Cost-effectiveness of DPYD Genotyping Prior to Fluoropyrimidine-based Adjuvant Chemotherapy for Colon Cancer



      Adjuvant fluoropyrimidine-based chemotherapy substantially reduces recurrence and mortality after resection of stage 3 colon cancer. While standard doses of 5-fluorouracil and capecitabine are safe for most patients, the risk of severe toxicity is increased for the approximately 6% of patients with dihydropyimidine dehydrogenase (DPD) deficiency caused by pathogenic DPYD gene variants. Pre-treatment screening for pathogenic DPYD gene variants reduces severe toxicity but has not been widely adopted in the United States.


      We conducted a cost-effectiveness analysis of DPYD genotyping prior to fluoropyrimidine-based adjuvant chemotherapy for stage 3 colon cancer, covering the c.1129-5923C>G (HapB3), c.1679T>G (*13), c.1905+1G>A (*2A), and c.2846A>T gene variants. We used a Markov model with a 5-year horizon, taking a United States healthcare perspective. Simulated patients with pathogenic DPYD gene variants received reduced-dose fluoropyrimidine chemotherapy. The primary outcome was the incremental cost-effectiveness ratio (ICER) for DPYD genotyping.


      Compared with no screening for DPD deficiency, DPYD genotyping increased per-patient costs by $78 and improved survival by 0.0038 quality-adjusted life years (QALYs), leading to an ICER of $20,506/QALY. In 1-way sensitivity analyses, The ICER exceeded $50,000 per QALY when the cost of the DPYD genotyping assay was greater than $286. In probabilistic sensitivity analysis using a willingness-to-pay threshold of $50,000/QALY DPYD genotyping was preferred to no screening in 96.2% of iterations.


      Among patients receiving adjuvant chemotherapy for stage 3 colon cancer, screening for DPD deficiency with DPYD genotyping is a cost-effective strategy for preventing infrequent but severe and sometimes fatal toxicities of fluoropyrimidine chemotherapy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Meyers BM
        • Cosby R
        • Quereshy F
        • Jonker D.
        Adjuvant chemotherapy for stage II and III colon cancer following complete resection: a cancer care ontario systematic review.
        Clin Oncol (R Coll Radiol). 2017; 29: 459-465
        • Innocenti F
        • Mills SC
        • Sanoff H
        • Ciccolini J
        • Lenz HJ
        • Milano G.
        All you need to know about DPYD genetic testing for patients treated with fluorouracil and capecitabine: a practitioner-friendly guide.
        JCO Oncol Pract. 2020; 16: 793-798
        • Andre T
        • Boni C
        • Mounedji-Boudiaf L
        • et al.
        Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
        N Engl J Med. 2004; 350: 2343-2351
        • Grothey A
        • Sobrero AF
        • Shields AF
        • et al.
        Duration of adjuvant chemotherapy for stage III colon cancer.
        N Engl J Med. 2018; 378: 1177-1188
        • Lee AM
        • Shi Q
        • Pavey E
        • et al.
        DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
        J Natl Cancer Inst. 2014; 106
        • Terrazzino S
        • Cargnin S
        • Del Re M
        • Danesi R
        • Canonico PL
        • Genazzani AA.
        DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis.
        Pharmacogenomics. 2013; 14: 1255-1272
        • Rosmarin D
        • Palles C
        • Church D
        • et al.
        Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.
        J Clin Oncol. 2014; 32: 1031-1039
        • Deenen MJ
        • Meulendijks D
        • Cats A
        • et al.
        Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis.
        J Clin Oncol. 2016; 34: 227-234
        • Sharma BB
        • Rai K
        • Blunt H
        • Zhao W
        • Tosteson TD
        • Brooks GA.
        Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis.
        Oncologist. 2021; 26: 1008-1016
        • van Kuilenburg AB.
        Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil.
        Eur J Cancer. 2004; 40: 939-950
        • Mattison LK
        • Fourie J
        • Desmond RA
        • Modak A
        • Saif MW
        • Diasio RB.
        Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians.
        Clin Cancer Res. 2006; 12: 5491-5495
        • Meulendijks D
        • Henricks LM
        • Jacobs BAW
        • et al.
        Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity.
        Br J Cancer. 2017; 116: 1415-1424
        • Henricks LM
        • Lunenburg C
        • de Man FM
        • et al.
        DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
        Lancet Oncol. 2018; 19: 1459-1467
        • Boisdron-Celle M
        • Capitain O
        • Faroux R
        • et al.
        Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: assessment of a multiparametric approach.
        Semin Oncol. 2017; 44: 13-23
        • Lunenburg C
        • Henricks LM
        • Guchelaar HJ
        • et al.
        Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time.
        Eur J Cancer. 2016; 54: 40-48
        • Husereau D
        • Drummond M
        • Petrou S
        • et al.
        Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
        Value Health. 2013; 16: 231-250
        • Lee AM
        • Shi Q
        • Alberts SR
        • et al.
        Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance).
        Pharmacogenet Genomics. 2016; 26: 133-137
      1. ARUP Laboratories. Dihydropyrimidine Dehydrogenase (DPYD), 3 Variants. Vol 2021.

        • Toffoli G
        • Innocenti F
        • Polesel J
        • et al.
        The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice.
        Clin Pharmacol Ther. 2019; 105: 994-1002
        • Surveillance, Epidemiology, and End Results (SEER) Program
        SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (2000-2016) <Katrina/Rita Population Adjustment>- Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission.
        National Cancer Institute, Bethesda, MD2019
      2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators.
        Lancet. 1995; 345: 939-944
        • Best JH
        • Garrison LP
        • Hollingworth W
        • Ramsey SD
        • Veenstra DL.
        Preference values associated with stage III colon cancer and adjuvant chemotherapy.
        Qual Life Res. 2010; 19: 391-400
        • Ramsey SD
        • Andersen MR
        • Etzioni R
        • et al.
        Quality of life in survivors of colorectal carcinoma.
        Cancer. 2000; 88: 1294-1303
      3. Clinical Laboratory Fee Schedule Files. Vol 2021.

        • Roeland E
        • Nipp RD
        • Ruddy KJ
        • et al.
        Inpatient hospitalization costs associated with nausea and vomiting among patients with cancer.
        J Clin Oncol. 2018; : 152
        • Mariotto AB
        • Yabroff KR
        • Shao Y
        • Feuer EJ
        • Brown ML.
        Projections of the cost of cancer care in the United States: 2010-2020.
        J Natl Cancer Inst. 2011; 103: 117-128
        • Dunn A
        • Grosse SD
        • Zuvekas SH.
        Adjusting health expenditures for inflation: a review of measures for health services research in the United States.
        Health Serv Res. 2018; 53: 175-196
        • Shankaran V
        • Ortendahl JD
        • Purdum AG
        • et al.
        Cost-effectiveness of cetuximab as first-line treatment for metastatic colorectal cancer in the United States.
        Am J Clin Oncol. 2018; 41: 65-72
        • Goldstein DA
        • Chen Q
        • Ayer T
        • et al.
        Bevacizumab for metastatic colorectal cancer: a global cost-effectiveness analysis.
        Oncologist. 2017; 22: 694-699
        • Sherman SK
        • Lange JJ
        • Dahdaleh FS
        • et al.
        Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer.
        JAMA Oncol. 2019; 5: 236-242
        • Henricks LM
        • Lunenburg C
        • de Man FM
        • et al.
        A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy.
        Eur J Cancer. 2019; 107: 60-67
        • Murphy C
        • Byrne S
        • Ahmed G
        • et al.
        Cost implications of reactive versus prospective testing for dihydropyrimidine dehydrogenase deficiency in patients with colorectal cancer: a single-institution experience.
        Dose Response. 2018; 161559325818803042
      4. DPYD genotyping in patients who have planned cancer treatment with fluoropyrimidines: a health technology assessment.
        Ont Health Technol Assess Ser. 2021; 21: 1-186
        • Cortejoso L
        • García-González X
        • García MI
        • García-Alfonso P
        • Sanjurjo M
        • López-Fernández LA.
        Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
        Pharmacogenomics. 2016; 17: 979-984
        • Hicks JK
        • Howard R
        • Reisman P
        • et al.
        Integrating somatic and germline next-generation sequencing into routine clinical oncology practice.
        JCO Precis Oncol. 2021; : 884-895
      5. European Medicines Agency. 5-Fluorouracil (i.v.), capecitabine and tegafur containing products: Pre-treatment testing to identify DPD-deficient patients at increased risk of severe toxicity. Vol 2021.

        • da Rocha JEB
        • Lombard Z
        • Ramsay M.
        Potential Impact of DPYD Variation on Fluoropyrimidine Drug Response in sub-Saharan African Populations.
        Front Genet. 2021; 12626954